At a glance
- Hexarelin, also called examorelin, is a synthetic six-amino-acid ghrelin-receptor agonist. It is studied in pituitary growth-hormone release and in exploratory cardiovascular models.
- Hexarelin is not an approved medicine. Acute hormone-release studies and preclinical cardiovascular findings do not establish long-term anti-aging, muscle, recovery, or heart benefits in people.
- Use time-resolved GH, ACTH, cortisol, and prolactin measurements to map both primary and spillover endocrine signals.
- Compare with ipamorelin or GHRP-2 at matched molar exposure when selectivity is the research question.
What HEXARELIN is—and what the name does not establish
Hexarelin, also called examorelin, is a synthetic six-amino-acid ghrelin-receptor agonist. It is studied in pituitary growth-hormone release and in exploratory cardiovascular models.
Hexarelin activates GHSR1a, producing a strong GH-release signal and, in some settings, smaller ACTH, cortisol, or prolactin responses. In plain language, it uses the ghrelin receptor like other GHRPs but has its own potency and endocrine profile.
Questions to settle before interpreting a result
A useful HEXARELIN study begins with material identity, a defined model, a relevant comparator, and an endpoint chosen before the result is known. Broad catalogue language cannot replace those controls.
- Use time-resolved GH, ACTH, cortisol, and prolactin measurements to map both primary and spillover endocrine signals.
- Compare with ipamorelin or GHRP-2 at matched molar exposure when selectivity is the research question.
- Keep pituitary GH-release work separate from exploratory direct cardiovascular or tissue-response studies.
How to read the HEXARELIN evidence
These evidence snapshots summarize the most important distinctions in the published record. They do not combine unlike models or turn an experimental signal into a human-use claim.
Human endocrine evidence
- Design
- Potent acute GH release has been documented
- Finding
- Small human physiology studies support GHSR-mediated GH secretion. They do not establish durable changes in muscle, body composition, recovery, or health outcomes.
- Read with care
- This is an interpretation boundary, not a claim that a specific outcome has been established in people.
Selectivity
- Design
- Other pituitary-adrenal signals can move too
- Finding
- Compared with ipamorelin, hexarelin may produce more ACTH, cortisol, or prolactin activity in some settings. Those hormones belong in a careful comparison.
- Read with care
- This is an interpretation boundary, not a claim that a specific outcome has been established in people.
Evidence boundary
- Design
- Cardiovascular animal signals remain exploratory
- Finding
- Preclinical heart and vascular findings can guide mechanism studies but do not establish a cardiac treatment or clinical protection.
- Read with care
- This is an interpretation boundary, not a claim that a specific outcome has been established in people.
What the evidence does not establish
Hexarelin is not an approved medicine. Acute hormone-release studies and preclinical cardiovascular findings do not establish long-term anti-aging, muscle, recovery, or heart benefits in people.
Mechanism, cell, animal, observational, and controlled human evidence answer different questions. A positive result at one level cannot be silently promoted to another, and evidence for a sponsor’s defined product does not establish equivalence for an independently sourced research material.
Keep the publication and the vial separate
A published paper identifies its own sequence or chemical identity, formulation, manufacturing context, analytical controls, exposure, and test system. Matching a familiar name on a label is not enough to show that a catalogue vial is the same study material.
For practical research planning, verify the lot-specific identity and documentation, then write the model, comparator, endpoint, and stopping criteria before testing. This guide does not provide preparation, dosing, injection, or human-use instructions.
Sources
Links lead to the paper, official registry, regulator page, or product label used for this guide. Registry records describe protocols and status; they are not treated as positive results.
- Growth hormone-releasing activity of hexarelin in humansPubMed-indexed human pharmacology study · 1994
Early acute human hormone-response study. It does not establish durable performance, body-composition, recovery, or cardiovascular outcomes.
- Think twice before injecting peptides bought online: unauthorized products can seriously harm youHealth Canada · 2026
Official Canadian advisory explaining that a research-use label does not establish authorization, safety, efficacy, or product quality for human use.
Vote for HEXARELIN
This compound is not currently stocked. Add it to your five-choice catalogue ballot.